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Neurotrophic small molecules have the potential to
aid in the treatment of neuronal injury and neurode-
generative diseases. The natural product fellutamide
B, originally isolated from Penicillium fellutanum,
potently induces nerve growth factor (NGF) release
from fibroblasts and glial-derived cells, although
the mechanism for this neurotrophic activity has
not been elucidated. Here, we report that fellutamide
B potently inhibits proteasome catalytic activity.
High-resolution structural information obtained
from cocrystallization of the 20S proteasome reveals
novel aspects regarding b-subunit binding and ad-
duct formation by fellutamide B to inhibit their hydro-
lytic activity. We demonstrate that fellutamide B and
other proteasome inhibitors increased NGF gene
transcription via a cis-acting element (or elements)
in the promoter. These results demonstrate an unrec-
ognized connection between proteasome inhibition
and NGF production, suggesting a possible new
strategy in the development of neurotrophic agents.
INTRODUCTION
The development of neurotrophic therapeutics for treatment of
neuronal injury or the neurodegenerative effects of stroke, is-
chemia, and CNS diseases (e.g., Parkinson’s disease and Alz-
heimer’s disease) has attracted much attention. In particular,
the neuroprotective and restorative effects of nerve growth fac-
tor (NGF) or other neurotrophins (reviewed in Huang and Reich-
ardt, 2003) in ameliorating the symptoms or pathophysiology in
animal models of the disease(s) have been documented in the lit-
erature (Castellanos-Ortega et al., 1999). For example, cotrans-
plantation of NGF along with fetal ventral mesencephalic cells
into the striatum of lesioned rats (a model of Parkinson’s disease)
significantly restored spontaneous locomotor activity and striatal
and nigral dopamine levels, compared with those in rats receiv-
ing transplanted cells alone (Chaturvedi et al., 2006). These re-
sults suggested that NGF both exhibited neuroprotective effects
on the transplanted cells and helped rescue remaining host do-
paminergic neurons from cell death. Similarly, NGF can attenu-Chemistry & Biologate lesion-induced cholinergic deficits and cognitive impair-
ments in animal models of Alzheimer’s disease: chronic NGF
treatment induced increased blood flow and nicotine uptake in
the cerebral cortex (Lapchak, 1993), and implantation of geneti-
cally engineered NGF-secreting fibroblasts into the brains of pa-
tients with early-stage Alzheimer’s disease significantly slowed
cholinergic nerve deterioration (Tuszynski et al., 2005). However,
the requirement for direct administration of neurotrophins or
large molecules into the CNS to circumvent the blood-brain bar-
rier severely limits their therapeutic utility and is not without side
effects (Venero et al., 1996). Efforts to promote penetration of
NGF across the blood-brain barrier by conjugating it to transfer-
rin (Liao et al., 2001) have been made; however, the amount of
modified NGF detected in the CNS was very small.
The development of small molecule neurotrophic compounds
capable of entering the brain is, therefore, an attractive thera-
peutic strategy. Literature reports have described small mole-
cules that are able to up-regulate selected neuronal proteins or
induce neurite outgrowth of cultured preneuronal cells (Cheng
et al., 2006; Warashina et al., 2006). However, the mechanism(s)
whereby such molecules act and the extent to which they can
completely mimic the actions of endogenous neurotrophins are
yet unknown. The fellutamides are marine fungal metabolites
(Shigemori et al., 1991) reported to induce the synthesis and se-
cretion of NGF (Yamaguchi et al., 1993) from cultured brain cells
and fibroblasts. Thus, fellutamide B might be considered an
‘‘indirect neurotrophin,’’ in much the same manner as a drug such
as reserpine, which triggers the release of norepinephrine from
presynaptic vesicles, is considered an indirect adrenergic ago-
nist. An indirect neurotrophic small molecule is likely to reap
the combined benefits of easier CNS access and the ultimate
therapeutic effects of the induced endogenous proteins. We re-
cently reported the first total synthesis of fellutamide B (Schnee-
kloth et al., 2006). Here, we explore the mechanism by which fell-
utamide B exerts its neurotrophin-inducing effect. We show that
fellutamide B potently inhibits the 20S proteasome, leading to
increased NGF gene expression and secretion.
RESULTS
Functional and Structural Evidence of Proteasome
Inhibition by Fellutamide B
Given the similarity in chemical structure between fellutamide B
and peptide aldehyde proteasome inhibitors (as exemplified byy 15, 501–512, May 2008 ª2008 Elsevier Ltd All rights reserved 501
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NGF Up-Regulation by Proteasome InhibitionFigure 1. Inhibition of Proteasome Activities by Fellutamide B and Other Inhibitors
(A) Chemical structures of fellutamide B and the known peptide-aldehyde proteasome inhibitor, MG132. Their respective active aldehyde groups are boxed
in red.
(B) Fellutamide B inhibits the chymotryptic-like, the tryptic-like, and the caspase-like activities of the mammalian proteasome. Proteolytic reactions were initiated
by addition of proteasomes to premixed substrate and inhibitor. Results presented are the mean ± standard error of three independent experiments.
(C) Potency of fellutamide B versus other proteasome inhibitors to inhibit chymotryptic-like activity of mammalian proteasome. Proteolytic reactions were initiated
by addition of proteasomes to premixed substrate and inhibitor. Results presented are the mean ± standard error of three independent experiments.
(D) Fellutamide B treatment causes accumulation of ubiquitinated proteins in vivo similar to other proteasome inhibitors (top panel). L-M cells were treated for 2 hr
with either 10 mM fellutamide B, 500 nM epoxomicin, 25 mM MG 132, or 0.1% DMSO (vehicle control); corresponding a-tubulin levels (bottom panel).MG132; Figure 1A), we investigated whether fellutamide B could
inhibit the three hydrolytic activities of the 20S proteasome. As
shown in Figure 1B, fellutamide B potently inhibits the chymo-
tryptic-like activity with an IC50 of 9.4 ± 2.5 nM. The tryptic-like
and caspase-like activities were also inhibited by fellutamide
B, albeit less potently (2.0 ± 0.4 mM and 1.2 ± 0.8 mM, respec-
tively). The potency of fellutamide B against the chymotryptic-
like activity was, in fact, greater than that of the peptide aldehyde
inhibitor MG132 (40 ± 3.3 nM) and approached the high potency
seen with the irreversible proteasome inhibitor (Meng et al.,
1999b) epoxomicin (5.7 ± 1.3 nM) (Figure 1C). As with the other
two established proteasome inhibitors, treatment of L-M mouse
fibroblasts with fellutamide B led to accumulation of ubiquiti-
nated proteins (Figure 1D), confirming its ability to inhibit the pro-
teasome in intact cells.
We next determined the crystal structure of the yeast 20S pro-
teasome in complex with fellutamide B to reveal its mechanism
of inhibition. The electron density was well defined in all active
sites, showing fellutamide B covalently bound to each active
site by a hemiacetal bond formed between its functional alde-
hyde group and the Thr1 g-oxygen (Figure 2A), similar to other502 Chemistry & Biology 15, 501–512, May 2008 ª2008 Elsevier Ltdaldehyde inhibitors, such as calpain inhibitor I, for which the
crystal structure is also well defined (Groll et al., 1997; Lo¨we
et al., 1995). However, the carbonyl-oxygen of the hemiacetal
formed by fellutamide B is hydrogen bridged to the Thr1 N termi-
nus (2.9 A˚); this differs from the interaction between the carbonyl
oxygen of calpain inhibitor I and the backbone amide of Gly47
(Figure 2B). This difference is especially noteworthy because
previous data on aldehyde inhibitors had defined the backbone
amide of Gly47 as the stereotypical oxyanion hole stabilizing
the transition state intermediate by hydrogen bonding to the
carbonyl group of the peptide bond undergoing hydrolysis.
It is known that aldehydes act as proteasome inhibitors only if
they contain a peptide backbone that allows their stabilization at
the proteasomal active sites through formation of an antiparallel
b sheet structure. These interactions are necessary to increase
the mean residence time of the ligand at the active center. By
varying their peptide backbone, proteasome inhibitors sharing
the same reactive functional group show preference for certain
active sites (Myung et al., 2001). Compared with other aldehyde
proteasome inhibitors, fellutamide B also contains an extended
b-hydroxy aliphatic tail. Surprisingly, the whole aliphatic tail,All rights reserved
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NGF Up-Regulation by Proteasome InhibitionFigure 2. Structural Data of Fellutamide
B Cocrystallized with S. cerevisiae 20S
Proteasome
(A) Fellutamide B (yellow) bound to the chymotryp-
tic-like subunit (b5) of the proteasome (space filling
model).
(B) Distinct stabilization of hemiacetal carbonyl-
oxygen (red) of fellutamide B (green) by Thr1
versus that of calpain inhibitor I (yellow) by Gly47.
The chymotryptic-like subunit is gray, and the
hemiacetal bond itself is pink. The inhibitor hydro-
gen-bonding elements within the chymotryptic-
like subunit—Thr1 and Gly47—are colored black.
(C) Different, subunit-specific orientations of the al-
iphatic tail of fellutamide B. Fellutamide B is
colored green, yellow, and blue, when bound to
the chymotryptic-like (b5), tryptic-like (b1), and cas-
pase-like (b2) proteasomal subunits, respectively.
(D) Electron density diagram showing fellutamide
B (green) interacting with designated residues
(black) along the specificity pocket of the chymo-
tryptic-like active site of the proteasome.which shows high flexibility in solution, has well-defined elec-
tron density at all proteolytic active sites. This stands in contrast
to synthetic long-chain aldehyde inhibitors, which are structur-
ally ordered only in their first three residues (Loidl et al., 1999).
Interestingly, structural superposition of fellutamide B bound
to the proteolytic active sites indicates that, although the pep-
tide backbone adopts similar conformations, the orientation of
the aliphatic tail differs completely (Figure 2C). In particular,
and uniquely at the chymotryptic-like subunit, C24 to C29 of
the fellutamide B aliphatic tail (Figure 1A) interact with a hydro-
phobic groove through van der Waals forces with protein resi-
dues Pro95, Tyr96, Pro115, and Val116 of subunit b6 (Figure 2D).
Interestingly, the hydrophobic groove to which the aliphatic tail
is bound is formed only during ligand binding, following con-
certed movements of the aliphatic tail and protein side chain
residues.Chemistry & BiologNeurotrophic Effects of Fellutamide B and Other
Proteasome Inhibitors on Mammalian Cells
Fellutamide B induces NGF secretion from a number of cells that
previously have been used as models to study NGF synthesis
and secretion (Table 1). All five of these cell lines (L-M, NIH
3T3, S-180, A172, and C6-2B cells) responded to 10 mM felluta-
mide B treatment by up-regulating NGF secretion, as detected
by ELISA of culture medium. L-M cells secreted the most NGF
overall and also exhibited the most robust response to the
drug, a 16.8-fold average induction, whereas NIH 3T3 cells
also responded to fellutamide B with an average 15.8-fold in-
crease in NGF secretion. S-180 sarcoma cells increased NGF
secretion by only 4.0-fold, although perhaps these tumor cells
by their very nature are already operating at nearly their maxi-
mum capacity to produce this neurotrophin. By comparison,
the two glial-derived cell lines, A172 and C6-2B, secreted NGFTable 1. Biological Activities of Fellutamide B at Various Cell Lines
Cell Line Tissue Type
NGF secretion:
vehicle-treated
(0.1% DMSO)
NGF secretion: 10 mM
fellutamide B-treated
Growth Arrest
([3H]-thymidine) IC50
Cytotoxicity (MTS
conversion) IC50
S180 Sarcoma 1.1 ± 0.4 ng/ml 4.5 ± 1.5 ng/ml 3.39 ± 0.59 mM 4.12 ± 0.34 mM
NIH 3T3 Fibroblast 0.3 ± 0.2 ng/ml 4.7 ± 2.0 ng/ml 3.40 ± 0.79 mM 4.62 ± 0.44 mM
L-M Fibroblast 3.0 ± 1.6 ng/ml 50.3 ± 14.9 ng/ml 397 ± 44.9 nM 2.24 ± 0.28 mM
A172 Glioblastoma 19.4 ± 4.7 pg/ml 95.9 ± 35.8 pg/ml 347 ± 59.1 nM 852 ± 77.5 nM
C6-2B Glioma 9.4 ± 4.4 pg/ml 61.7 ± 29.1 pg/ml 473 ± 143 nM 1.52 ± 0.25 mM
KB Epidermoid carcinoma None detected None detected 257 ± 46.1 nM 342 ± 82.8 nM
P-388 Leukemia None detected None detected 4.26 ± 0.85 mM 7.80 ± 1.9 mM
PC12 Pheochromocytoma None detected None detected 403 ± 19.9 nM 565 ± 106 nM
Fellutamide B treatment was for 24 hr, and values reported are the mean ± standard error of at least three independent experimental determinations.y 15, 501–512, May 2008 ª2008 Elsevier Ltd All rights reserved 503
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NGF Up-Regulation by Proteasome InhibitionFigure 3. Treatment of L-M Cells with Fellutamide B or Other Proteasome Inhibitors Induces Secretion of NGF
(A) Fellutamide B treatment for 24 hr induces dose-dependent secretion of NGF from L-M cells.
(B) Cytotoxicity of 24 hr fellutamide B treatment against L-M cells.
(C) Effectiveness of short (‘‘pulse’’) fellutamide B treatments to induce NGF up-regulation in L-M cells.
(D) Cytotoxicity of short (‘‘pulse’’) fellutamide B treatments against L-M cells.
(E) Epoxomicin induces secretion of NGF from L-M cells.
(F) MG132 induces secretion of NGF from L-M cells. Data presented are the means ± standard deviation of three independent experiments.
(G) Conditioned medium from L-M cells treated with proteasome inhibitors causes differentiation of preneuronal PC12 cells. Representative images presented of
PC12 cells in conditioned medium from vehicle (0.1% DMSO)-treated L-M cells; from 10 mM fellutamide B-treated L-M cells; and from 250 nM epoxomicin-
treated L-M cells.on a much smaller scale; however, both responded to felluta-
mide B by increasing their NGF production by 4.9-fold and 6.6-
fold, respectively. Not every cell type tested responded to fellu-
tamide B. KB epidermal carcinoma cells and P-388 leukemia
cells were used in the original report on the discovery of this
small molecule (Shigemori et al., 1991). Both failed to show a re-
sponse to the drug in terms of NGF secretion, despite their re-
ported sensitivity to the growth inhibitory effects of fellutamide
B. Likewise, the preneuronal cell line PC-12 (rat pheochromocy-
toma), which can differentiate into a neuronal phenotype in the
presence of NGF (Obin et al., 1999), also failed to show detect-
able NGF secretion in the presence of fellutamide B by either
ELISA (Table 1) or neurite outgrowth (unpublished data). Felluta-
mide B causes cell cycle arrest (measured by [3H]-thymidine in-
corporation into cellular DNA) in all the cell lines on which it was504 Chemistry & Biology 15, 501–512, May 2008 ª2008 Elsevier Ltdtested (Table 1). In most cell lines, this growth arrest resulted
from the cytoxicity of fellutamide B (measured by MTS conver-
sion by active mitochondria in Table 1), although in a few in-
stances—L-M cells and, to a lesser extent, C6-2B and A172
cells—the IC50 for growth arrest was lower than that observed
for cytotoxicity. Thus, although the growth inhibitory/cytotoxic
activity of fellutamide B appears to affect all cells, its activity to
elicit NGF up-regulation is restricted to a subset of cell types.
Because L-M cells displayed the most robust NGF response,
this cell line was selected for further analysis of fellutamide B
activities: as shown in Figure 3A, the potency with which felluta-
mide B induces NGF in L-M cells is similar to its cytotoxicity in
MTS conversion assay (Figure 3B). The bond formed between
proteasome catalytic subunits and peptide aldehyde inhibitors
such as fellutamide B is reversible. Thus, it was hypothesizedAll rights reserved
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NGF Up-Regulation by Proteasome Inhibitionthat a brief administration of fellutamide B for a few hours
(a ‘‘pulse’’) followed by a drug-free ‘‘recovery’’ interval—rather
than a continuous 24 hr fellutamide B treatment—might result
in significant NGF induction with reduced cytotoxicity, com-
pared with continuous drug treatment. It was found that 7 hr
pulse of 10 mM fellutamide B was sufficient to elicit 90% of the
maximal NGF up-regulation that had been induced by 24 hr of
continuous treatment (Figure 3C). However, the reduction in
cell viability (Figure 3D) associated with the 7 hr pulse was only
35.0%, which was markedly reduced, compared with the
60.0% reduction seen with the continuous 24 hr treatment.
Thus, although an exclusively neurotrophic and nontoxic con-
centration of fellutamide B was not apparent, the two activities
of fellutamide B can yet be largely dissociated from each other
by the proper duration of treatment.
Having now confirmed the NGF-inducing activity of felluta-
mide B and having also shown it to be a proteasome inhibitor,
we tested whether this NGF-inducing activity could be general-
ized to other proteasome inhibitors. Similar to fellutamide B,
the established proteasome inhibitors epoxomicin and MG132
triggered NGF up-regulation in the L-M cells with EC50 values
of 127 ± 13.4 nM and 11.8 ± 3.7 mM, respectively (Figures 3E
and 3F). This finding confirms that proteasome inhibition is the
key activity of fellutamide B, because epoxomicin is a highly spe-
cific inhibitor of the proteasome that does not inhibit other prote-
ases. Although we observed that fellutamide B and the other pro-
teasome inhibitors induced up-regulation of NGF less potently
than they inhibited the purified proteasomes, this finding is likely
the result of the inherent differences between the two assays. In-
tact cells were required in the NGF secretion assay and in the
anti-ubiquitin Western blots in Figure 1D; thus, such factors as
membrane permeation, drug-efflux pumps (e.g., P-glycopro-
tein), and deubiquitinases that often reduce the apparent
potency of these drugs would have attenuating effects. Such
factors are absent from our measurements on the purified
proteasome activity, which cannot be accurately, specifically
made in intact cells because of the interfering presence of free
proteases. Nevertheless, the rank order potency with which
these compounds induce NGF secretion corresponds to their
rank order potency for inhibiting the proteasomal chymotryp-
tic-like activity. The biological activity of the secreted NGF was
confirmed by incubating undifferentiated PC12 cells in medium
that had been conditioned by fellutamide B- or epoxomicin-
treated L-M cells. PC12 neurite outgrowth was readily observ-
able after incubation for only 24 hr (data not shown) and was
pronounced after incubation for 48 hr in conditioned medium
(Figure 3G).
Given the cytotoxicity accompanying fellutamide B treatment,
the question remained whether NGF induction was a conse-
quence of proteasome inhibition specifically or rather a response
to general cytotoxic insult. To answer this question, L-M cells
were separately exposed (Figure 4A) to three different toxic
treatments: (1) a combination of veratridine and ouabain, to col-
lapse the membrane potential; (2) a combination of cytochalasin
D and myoseverin, to destroy the cytoskeleton; and (3) epoxomi-
cin, a structurally dissimilar proteasome inhibitor. In the case of
fellutamide B and epoxomicin, these agent(s) induced the forma-
tion of long cell processes that, in the past, had been misinter-
preted as neurites (Fenteany et al., 1994) when observed onChemistry & Biologyneuronal cell lines. All treatments were comparably cytotoxic,
as measured by MTS conversion assay (Figure 4C), which West-
ern blotting for cleavage of the caspase 3 substrate PARP (Fig-
ure 4B) showed was due to apoptotic cell death. However,
only fellutamide B and epoxomicin triggered up-regulation of
NGF (Figure 4D). Thus, the neurotrophic effects of fellutamide
B appear to be a specific consequence of proteasome inhibition
rather than a cellular response to general cytotoxicity.
Up-Regulation of NGF Occurs by Induction of Gene
Transcription from both NGF Promoters
To provide further mechanistic insight into proteasome inhibitor-
induced NGF up-regulation, we next examined the effect of
fellutamide B on NGF gene transcription. Specifically, the levels
of NGF mRNA from fellutamide B- versus vehicle-treated cells
were measured using RT-PCR. These results (Figure 5A)
showed a robust up-regulation of NGF mRNA in response to
the proteasome inhibitor, whereas measurements of the house-
keeping transcript GAPDH showed no drug-associated changes.
There are, in fact, two known promoters for the NGF gene (Racke
et al., 1996): one upstream of the first exon, and another that
lies between exons 2 and 3, with the entire protein-coding region
located in exon 4. The mRNAs produced from the two NGF pro-
moters can be distinguished by their differentially retained
exons. Our RT-PCR results show that NGF mRNA transcripts
from both known promoters are strongly up-regulated following
fellutamide B treatment (Figure 5A); note that two mRNA tran-
scripts of slightly different sizes are detected from the upstream
promoter, as described elsewhere (Racke et al., 1996). The
magnitude of this increase in NGF mRNA following proteasome
inhibitor treatment may be sufficient to account for the increases
in NGF at the protein level. To confirm that the up-regulation of
NGF was due to NGF mRNA transcription, a time course of
fellutamide-triggered NGF induction in both the absence and
presence of the RNA polymerase II inhibitor, a-amanitin, was
performed. Following 12 hr of continuous fellutamide B treat-
ment, the levels of secreted NGF began to increase (Figure 5B);
this increase was completely blocked at all times by the pres-
ence of a-amanitin. This result is consistent with up-regulation
due to de novo NGF mRNA synthesis upon fellutamide B admin-
istration and rules out any independent role for posttranslational
up-regulation of NGF secretion. A parallel MTS assay showed
conclusively that the inhibition of NGF up-regulation by a-
amanitin cannot be attributed to additive cytotoxicity in combi-
nation with fellutamide B, because there was none (Figure 5C).
Furthermore, measurements of NGF mRNA stability in the
absence or presence of fellutamide B (Figure 5D) showed no
differences in rate of decay, demonstrating that up-regulation
of NGF mRNA in response to the small molecule was due only
to enhanced transcription and not to diminished transcript
degradation.
To focus on the region(s) of the NGF promoter mediating the
transcriptional activation response to proteasome inhibitors,
we subcloned the entire 5 kb mouse NGF promoter (D’Mello
and Heinrich, 1991), including the first 120 bp downstream of
the transcription start site (defined as position +1) into a promo-
terless firefly luciferase plasmid for gene reporter assays.
Upstream regions of the NGF promoter were progressively
removed to create plasmids (Figure 6A), which were stably15, 501–512, May 2008 ª2008 Elsevier Ltd All rights reserved 505
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NGF Up-Regulation by Proteasome InhibitionFigure 4. Secretion of NGF Is Not a Response to General Cytotoxicity
(A) Morphological changes to L-M cells in response to 24 hr treatment with depicted toxins (representative images presented).
(B) MTS conversion assay of L-M cells treated overnight with indicated toxins.
(C) Fellutamide B and other toxins trigger apoptotic cleavage of poly(ADP-ribose)polymerase (treatment for 24 hr).
(D) ELISA measurements of secreted NGF from L-M cells treated overnight with indicated toxins. Data presented are the means ± standard deviation of three
independent experiments.transfected into cells, along with SV40 early promoter-driven re-
nilla luciferase coreporter, and were tested for the ability of fell-
utamide B to induce firefly luciferase activity (Figure 6B). To en-
sure that any effects on reporter expression or regulation arising
from differing genomic integration points would be balanced
among the different reporter transfectants, pools of stably trans-
fected clones for each reporter were used. The full 5 kb NGF pro-
moter (5000 bp) was responsive to fellutamide B, showing
a nearly 6-fold induction of luciferase activity. Although trunca-
tion of the promoter down to 1.8 kb (1800 bp) increased overall
luciferase transcription (basal and drug induced), the level of in-
duction by fellutamide B remained approximately the same. Fur-
ther truncation of the promoter down to 750 bp (750 bp) and
then to 250 bp (250 bp) continued the trend of increasing over-506 Chemistry & Biology 15, 501–512, May 2008 ª2008 Elsevier Ltdall luciferase transcription, indicating the removal of postulated
gene suppressive elements from the promoter (D’Mello and
Heinrich, 1991). However, these reporters were still responsive
to fellutamide B and showed increased luciferase activity in its
presence. Given the importance of the AP-1 site at position
+35 in mediating the stimulatory effects of phorbol esters
(Omae et al., 1994) and dihydroxyvitamin D3 (Veenstra et al.,
1998) on NGF synthesis, and the fact that fellutamide B treat-
ment causes the stabilization and activation of c-Jun (authors’
unpublished data), we tested whether this AP-1 site is also cru-
cial for the effects of proteasome inhibitors. Reporter vectors
were constructed lacking the AP-1 site (1800 w/o AP-1;
750 w/o AP-1; and 250 w/o AP-1), but assays on cells trans-
fected with these constructs continued to show increasedAll rights reserved
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NGF Up-Regulation by Proteasome InhibitionFigure 5. Proteasome Inhibition Causes Up-Regulation of NGF Gene Transcription
(A) RT-PCR for NGF and GAPDH transcripts from extracted mRNA from 24 hr fellutamide B-treated and untreated cells: total NGF mRNA (top left), GAPDH (bot-
tom left), NGF mRNA transcribed from upstream promoter (top, right), and NGF mRNA transcribed from downstream promoter (bottom, right). Representative
results shown.
(B) Blockade of RNA polymerase II with a-amanitin (20 mg/ml) abolishes up-regulation of NGF secretion by fellutamide B (10 mM). White bars correspond to control
cells, black bars to fellutamide B-treated cells, and gray bars to fellutamide B plus a-amanitin-treated cells. Data presented are the means ± standard deviation of
three independent experiments.
(C) a-Amanitin and fellutamide B cotreatment does not result in additive cytotoxicity to L-M cells. Colored bars represent the same drug treatment as in (B). Data
presented are the means ± standard deviation of three independent experiments.
(D) Up-regulation of NGF mRNA levels by fellutamide B does not involve enhanced stabilization of NGF mRNA transcripts. RT-PCR was performed on mRNA
isolated from L-M cells treated with a-amanitin (20 mg/ml) and maintained with or without 10 mM fellutamide B for the times indicated. A representative time-
dependent decay of NGF mRNA from vehicle-treated (top panel) and fellutamide B-treated (bottom panel) cells is shown.luciferase activity in response to fellutamide B, although removal
of the AP-1 site had a diminishing effect on overall luciferase
transcription. Truncation of the promoter down to 150 bp re-
tained fellutamide B responsiveness, indicating that the cis-act-
ing element or elements lie close to the transcription start site.
Epoxomicin, MG 132, and clasto-lactacystin b-lactone all in-
duced luciferase (Figure 6C) from this minimal reporter plasmid,
verifying that this region of the NGF promoter was responsive to
proteasome inhibitors other than fellutamide B.
DISCUSSION
Our finding that proteasome inhibition leads to the production
and secretion of NGF reveals another potential therapeutic utility
of this class of small molecules. Proteasome inhibitors haveChemistry & Biologyalready been identified as candidate anti-inflammatory (Meng
et al., 1999b) and antitumor drugs (Meng et al., 1999a). They
have also been implicated in stimulating bone formation (Garrett
et al., 2003), the treatment of stroke (Phillips et al., 2000), and as
antiparasitic agents (Lindenthal et al., 2005). Although protea-
some inhibition can lead to cytotoxicity, therapeutic windows
have been established that nonetheless permit their use clini-
cally. Indeed, although continuous 24 hr treatment of the cells
with fellutamide B resulted in maximum NGF up-regulation and
toxicity, pulse treatment with fellutamide B for only 7 hr followed
by a 17 hr recovery interval resulted in a nearly equivalent induc-
tion of NGF with markedly reduced toxicity. The separation of
these two activities of fellutamide B—and, by extension, other
reversible proteasome inhibitors—is an important step in their
development as potential neurotrophic therapeutics. This is15, 501–512, May 2008 ª2008 Elsevier Ltd All rights reserved 507
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NGF Up-Regulation by Proteasome InhibitionFigure 6. A cis-Acting Element Within the NGF Promoter Is Induced by Proteasome Inhibitors
(A) Schematic of NGF promoter-driven luciferase reporters. White regions represent the NGF promoter and black regions represents firefly luciferase gene (not
to scale).
(B) Fellutamide activates a cis-acting element adjacent to the transcription start site. Data presented are NGF promoter-driven firefly luciferase reporter activity
normalized to SV40 early promoter-driven renilla luciferase coreporter. Results are the mean ± standard error of 3 to 5 independent experiments.
(C) Proteasome inhibitors other than fellutamide B induce via the same cis-acting element in the NGF promoter. Cells were stably transfected with the luciferase
reporter driven by the 150 bp upstream of the transcription start site in the NGF promoter (i.e., ‘‘150 bp w/o AP1’’). Results are the mean ± standard error of 3 to 5
independent experiments.less of a concern with fellutamide B than it will be with other pro-
teasome inhibitors: epoxomicin was the most potent inducer of
NGF but was also the most potently cytotoxic. This greater tox-
icity is almost certainly attributable to the fact that epoxomicin,
unlike fellutamide B and MG132, irreversibly inhibits the protea-
some, which placed an upper limit on the epoxomicin concentra-
tions that could be used on whole cells (e.g., Figures 1D and 3E)
and still produce the biological effect without killing them first.
This irreversible inhibition by epoxomicin ultimately makes it un-
suitable for the same pulse treatments that reduced the toxicity
of fellutamide B.
Application of such proteasome inhibitors as MG132 to trans-
ected axons significantly delays the onset of Wallerian degener-
ation (Zhai et al., 2003), both in vitro and in vivo. Given that per-
sistent activation of erk1/2 (MacInnis and Campenot, 2005),
a known downstream effector of NGF receptors, was also ob-
served in these studies, it is possible that the degeneration
was delayed by proteasome inhibitor-triggered up-regulation508 Chemistry & Biology 15, 501–512, May 2008 ª2008 Elsevier Ltdof NGF. The ability of some proteasome inhibitors to spur ‘‘neu-
rite outgrowth’’ from preneuronal cells has been reported many
times (Fenteany et al., 1994; Inoue et al., 2004); however, this ef-
fect is not specific to preneuronal cells and has been shown to
also occur in endothelial cells (Meng et al., 1999a) and, in the
present study, in L-M fibroblasts (Figure 4A). Straight et al.
(2003) have reported that proteasome inhibitors arrest dividing
cells in cytokinesis, which may be the basis for the spindle-like
morphology seen in treated cells. Thus, it is perhaps more accu-
rate to describe this proteasome inhibitor effect as a general
induction of a bipolar cellular elongation, which, in preneuronal
cells, was misinterpreted as ‘‘neurites.’’ However, NGF induction
by proteasome inhibition is a process that should elicit neuronal
differentiation, maintenance, and neuroprotection, because it
up-regulates the natural neurotrophin. Further evidence for the
independence of proteasome inhibitor-triggered process exten-
sion from NGF secretion is that fellutamide B failed to trigger the
latter in PC12 cells (data not shown), a system in which neuriteAll rights reserved
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extensively.
The structural data from the cocrystallization of fellutamide B
with the 20S proteasome reveal some interesting and unex-
pected insights into how inhibition is achieved. The data illustrate
the possibility of two different hemiacetal adduct enantiomers
(R,S) formed by peptide aldehyde inhibitors: (1) the customary
adduct with the planar aldehyde group oxygen atom pointing
into the oxyanion hole formed by Gly47-N, or, as now seen
with fellutamide B, (2) an alternative orientation of the aldehyde
group oxygen toward Thr1-NH. Although hydrogen bonding be-
tween the Thr1-N terminus and the active group of a small mol-
ecule inhibitor has been observed for other classes of inhibitors
(e.g., b-lactones; Borissenko and Groll, 2007), it is nonetheless
an unexpected finding for a peptide aldehyde proteasomal inhib-
itor that either orientiation can and will stabilize the hemiacetal
oxygen atom and thereby block catalytic activity (Borissenko
and Groll, 2007; Groll et al., 1997; Lo¨we et al., 1995). In addition
to the binding of fellutamide B’s P1 and P3 side chains to the
cognate S1 and S3 specificity pockets, the structural basis for
its preferential blockade of the chymotryptic-like active site
may also reside in the interaction of its distinctive aliphatic tail
with several residues in an adjacent hydrophobic groove. The al-
iphatic tail adopts dissimilar conformations when bound to the
tryptic-like and caspase-like active sites, such that the stabiliza-
tion of the aliphatic tail to the hydrophobic groove is peculiar to
the chymotryptic-like active site. This may contribute signifi-
cantly to the tighter binding of fellutamide B to that subunit,
translating into the observed 200- to 400-fold greater potency
to inhibit this activity (Figure 1B).
An earlier study (Yamaguchi et al., 1993) had shown decreas-
ing NGF secretion triggered by a maximum dose of fellutamide in
the presence of ever-increasing concentrations of actinomycin
D. This finding raised two possibilities: either the increasing,
combined cytotoxicity from blockade of both the proteasome
and transcription killed the cells before NGF could be produced,
or de novo NGF mRNA transcription is a necessary element in
the mechanism of fellutamide. We have, in fact, observed that
fellutamide B and other proteasome inhibitors exert a biphasic
effect on NGF secretion, increasing it until a critical concentra-
tion of proteasome inhibitor is reached, after which further in-
creases become overwhelmingly toxic and NGF secretion dimin-
ishes. Thus, a more rigorous examination of the involvement of
mRNA up-regulation in the effect of fellutamide B seemed partic-
ularly compelling. The data here show conclusively that in-
creased transcription of NGF mRNA is, indeed, necessary; in
fact, the increase in NGF mRNA following fellutamide B treat-
ment was so dramatic that it recommended that up-regulation
occurs exclusively at the mRNA level. This increase in NGF
mRNA involves activation of both known promoter regions for
the NGF gene, which is consistent with an earlier report implying
coordinate regulation of these two promoters (Racke et al.,
1996). Because the ultimate NGF protein products from these
two promoters are believed to be biologically equivalent, the
combined effect of proteasome inhibition would be that much
greater.
Although our own RT-PCR results clearly showed that NGF
mRNA was being up-regulated by fellutamide B, it was possible
that either degradation of the transcripts had been attenuated orChemistry & Biologytheir synthesis had been stimulated, or some combination of
both. The blockade of the neurotrophic response to fellutamide
B by a-amanitin suggested transcriptional activation of the
NGF gene and ruled out the possibility that increased NGF se-
cretion could be largely posttranslational (i.e., NGF protein traf-
ficking). Still, it did not eliminate the possibility that stabilization
of NGF mRNA contributed to the transcript up-regulation. Only
after showing that the decay of NGF mRNA remains the same
in the presence or absence of fellutamide B could we unambig-
uously conclude that transcriptional activation of the NGF gene
is the sole mechanism for increased production of the protein.
Furthermore, we were able to narrow the region of the NGF pro-
moter crucial for transcriptional activation down to within 150 bp
of the transcription start site and rule out participation of an
important AP-1 site at position +35.
Changes in levels of other proteins besides NGF are to be ex-
pected following treatment with proteasome inhibitors, which is
why these small molecules have therapeutic value for treating
many disease states. However, the broad effects of these small
molecules can also lead to potential limitations on their useful-
ness. For example, some uncertainty exists regarding the stabi-
lizing effect of proteasome inhibition on cytoplasmic levels of the
noninfectious form of the prion protein, PrPC. Although transmis-
sion of prion disease states depends on the presence of the mis-
folded ‘‘scrapie’’ form of the protein (PrPSc), Ma and Lindquist
(2001) reported that accumulation of PrPC following proteasome
inhibition can itself result in neuronal toxicity. Although subse-
quent reports (Fioriti et al., 2005; Kristiansen et al., 2005; Roucou
et al., 2003) strongly dispute the neurotoxic effect of elevated cy-
toplasmic PrPC, the effects of proteasome inhibitors on protein
levels other than NGF need to be carefully considered as their
potential for neuronal therapeutics is evaluated. Separating the
toxic effect of fellutamide B and other proteasome inhibitors
from their NGF-inducing properties is a crucial barrier toward
their ultimate development for any clinical use, neurotrophic or
otherwise. Although it was demonstrated that toxicity is not
a precondition for up-regulating NGF from the cell types tested,
toxicity is a side effect of proteasome inhibitors. There are, how-
ever, reasons to believe that these two activities of fellutamide B
are independent. For instance, not every cell tested herein re-
sponded to fellutamide B by up-regulating NGF, but all the cells
tested were sensitive to the cytotoxic effect of the proteasome
inhibitor. In addition, the aforementioned pulse-recovery strat-
egy of administering fellutamide B produced nearly maximum
NGF up-regulation with attenuated toxicity. Moreover, the
dose-response relationship of fellutamide B cytotoxicity clearly
differs from that of NGF induction in that the latter reaches max-
imum efficacy over a more narrow concentration range. As
shown in Figure 3B, the Hill slope for fellutamide B cytotoxicity
fits to unity, whereas that for its NGF induction (as well as
MG132 and epoxomicin) is 3.5 (as shown in Figures 3A, 3E,
and 3F). Although the molecular basis for this pharmacodynamic
difference is not known, it suggests the possibilities of positive
cooperativity or other positive feedback mechanism in the up-
regulation of NGF by fellutamide B or the activation of multiple
cis-elements over a narrow concentration range of fellutamide
B (non-first order induction); this is not seen with cytotoxicity.
Because the blockade of the proteasome affects the levels of
multiple proteins within the cell, it is reasonable to hypothesize15, 501–512, May 2008 ª2008 Elsevier Ltd All rights reserved 509
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will be different from those that mediate the toxic effect. Thus,
maximum NGF induction can be achieved at proteasome inhib-
itor conditions that do not elicit maximum toxicity.
It is encouraging that fellutamide B exerts its effects on both
glial and fibroblast cells. In terms of therapeutic potential,
a broader tissue effect would enable proteasomal inhibition to
treat both peripheral nerve injury, where fibroblasts would be
the predominant cell type to secrete the trophic factors, as well
as neurodegeneration in the brain, where glial cells are more
plentiful. Moreover, because many neurotrophins appear to be
coordinately regulated in the CNS (Maisonpierre et al., 1990;
Takeda et al., 1993), the possibility that proteasome inhibition
might have a similar trophic effect on other neurotrophins (e.g.,
NT-3 or BDNF) is an interesting possibility that remains to be
investigated.
SIGNIFICANCE
There is great interest in the fields of neuroscience and
chemical biology to identify compounds that either trigger
neuronal differentiation and survival or induce neurotrophin
expression. Such compounds would have great therapeutic
potential for the treatment of neuronal injury or neurodegen-
erative diseases. Although reports that identify such com-
pounds from library screens or natural sources are increas-
ing in frequency, none of these emerging studies has
identified a protein receptor or mechanism of action to
which the neurotrophic activity can be ascribed. We report
here that fellutamide B, one of the earliest compounds iden-
tified to have neurotrophin-inducing activity, does so by
binding to and inhibiting the 20S proteasome. Although the
manner in which fellutamide B binds to the proteasome is
distinct from other peptide aldehyde inhibitors, its ability to
up-regulate NGF is shared not only by other peptide alde-
hydes, but also by other mechanistically different classes
of proteasome inhibitors. Proteasome inhibitors and NGF
administration are known to attenuate Wallerian axonal de-
generation, and our results now suggest a direct connection
between these two neuroprotective approaches.
The proteasome has previously been targeted in the treat-
ment of cancer, inflammation, and stroke. Here, we have
identified another potential medical application for protea-
some inhibitors, some of which are already in clinical trials.
With the demonstrated efficacy of neurotrophins to alleviate
symptoms of neurodegenerative diseases, fellutamide B
and other proteasome inhibitors deserve further attention
as potential neuronal therapeutics.
EXPERIMENTAL PROCEDURES
Reagents
Fellutamide B (Schneekloth et al., 2006) and epoxomicin (Sin et al., 1999) were
synthesized as described elsewhere. MG 132, myoseverin, cytochalasin D,
clasto-lactacystin b-lactone, and a-amanitin were purchased from Calbio-
chem (La Jolla, CA). Veratridine and ouabain were obtained from Sigma
(St. Louis, MO). Fluorogenic substrate peptides for proteasome activity assay
were from Bachem Bioscience (King of Prussia, PA). Purified human 20S
proteasome were purchased from Boston Biochemical (Cambridge, MA).510 Chemistry & Biology 15, 501–512, May 2008 ª2008 Elsevier LtdCell Culture
C6-2B cells were a generous gift from Satya Kunapuli (Temple University, Phil-
adelphia, PA), and PC12 cells were a gift from Randy Pittman (University of
Pennsylvania, Philadelphia, PA); all other cell lines were purchased from
ATCC (Manassas, VA). Undifferentiated PC12 cells were grown in RPMI
1640 medium supplemented with 10% heat-inactivated horse serum and
5% heat-inactivated fetal bovine serum. L-M mouse fibroblasts were cultured
in Medium 199 supplemented with 0.5% peptone. NIH 3T3, C6-2B, and A172
cells were grown in high-glucose Dulbecco’s Modified Eagle Medium supple-
mented with 10% heat-inactivated fetal bovine serum, and S-180 cells were
cultivated in minimal essential medium supplemented with Earle’s salts, 2 mM
glutamine, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids. All
culture media was supplemented with 100 units/ml penicillin G and 100 mg/ml
streptomycin sulfate.
Cytotoxicity Assay
Following drug treatment of cells as indicated, culture medium was supple-
mented with 330 mg/ml MTS (Promega Corp., Madison, WI) and 25 mM phen-
azine methosulfate and was incubated at 37C. Mitochondrial reduction of
MTS to the formazan derivative was monitored by measuring the medium’s
absorbance at 490 nm.
Proliferation Assay
The proliferation assay was performed as described elsewhere (Yeh et al.,
2000). [3H]-thymidine was purchased from Perkin-Elmer Life Sciences
(Boston, MA).
Neurite Outgrowth Assay
L-M cells were treated with either 10 mM fellutamide B, 250 nM epoxomicin, or
vehicle control (0.1% DMSO) for 24 hr. Afterward, conditioned medium was
collected and dialyzed (MWCO = 10 kDa) against RPMI 1640 for 24 hr at
4C. The dialyzed, conditioned medium was then supplemented with 2%
heat-inactivated horse serum and 1% heat-inactivated fetal bovine serum
and was applied to undifferentiated PC12 cells growing on collagen-covered
60 mm dishes. The development of neurites was monitored over the following
48 hr.
NGF ELISA
ELISA for NGF was performed in accordance with the kit manufacturer’s rec-
ommended instructions (Promega Corp., Madison, WI). Data were analyzed
using PRISM software (GraphPad Software, San Diego, CA).
Western Blotting
Western blotting was performed as described elsewhere (Meng et al., 1999a).
Protein samples were resolved by 8% SDS-PAGE, were transferred to nitro-
cellulose, and were probed with antibodies to ubiquitin (Cell Signaling Tech.,
Danvers, MA), a-tubulin (Sigma, St. Louis, MO), or PARP (Zymed Labs, San
Francisco, CA).
Proteasome Activity Assay
The proteasome activity assay was performed according to a method
described in detail elsewhere (Kim et al., 2005).
RT-PCR
mRNA was extracted from fellutamide B-treated and vehicle-treated L-M cells
using Trizol reagent. First-strand synthesis of cDNA was performed using Su-
perScript III first-strand synthesis kit (Invitrogen, Carlsbad, CA). PCR measure-
ments of NGF and GAPDH were performed using the following primers:
total NGF forward primer (50-GCAGTGAGGTGCATAGCGTA-30 );
upstream promoter-derived NGF forward primer (50-AGAGAGCGCCTGG
AGCCG-30);
downstream promoter-driven NGF forward primer (50-CTTCCTGGGCT
CTAATGATGC-30);
total NGF reverse primer (50-CACTGAGAACTCCCCCATGT-30);
GAPDH forward primer (50-AACTTTGGCATTGTGGAAGG-30 ); and
GAPDH reverse primer (50-ACACATTGGGGGTAGGAACA-30).All rights reserved
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cDNA to verify changes (or lack thereof) in target abundance.
Cocrystallization of Fellutamide B and 20S Proteasome
Crystals of 20S proteasome from S. cerevisiae were grown in hanging drops at
24C, as described elsewhere (Groll and Huber, 2005), and were incubated for
60 min with fellutamide B (10 mM in DMSO). The protein concentration used for
crystallization was 40 mg/ml in 10 mM Tris$HCl (pH 7.5) and 1 mM EDTA.
Drops contained 3 ml of protein and 2 ml of reservoir solution (30 mM magne-
sium acetate, 100 mM morpholino-ethane-sulphonic acid [MES] [pH 7.2],
and 10% 2-methyl-2,4-pentanediol [MPD]). The space group of proteasomal
complex crystals belongs to P21 with cell dimensions of a = 134.3 A˚, b =
301.6 A˚, c = 143.5 A˚, and b = 112.7. Data to 2.6 A˚ were collected using syn-
chrotron radiation with l = 1.05 A˚ at the X06SA-beamline at the Paul Scherrer
Institut, Swiss Light Source (Villingen, Switzerland). Crystals were soaked in
cryoprotecting buffer (30% MPD, 20 mM magnesium acetate, and 100 mM
MES [pH 6.9]) and were frozen in a stream of liquid nitrogen gas at 90 K (Oxford
Cryo Systems, Oxford, UK). X-ray intensities were evaluated using the DENZO
program package, and data reduction was performed with SCALEPACK (Ot-
winowski et al., 2003; Otwinowski and Minor, 1997). Anisotropy of diffraction
was corrected by an overall anisotropic temperature factor, comparing ob-
served and calculated structure amplitudes using the program CNS (Bru¨nger
et al., 1998). A total of 796,875 reflections yielded 331,875 unique reflections
(98.7% completeness). The corresponding Rmerge was 6.6% at 2.6 A˚ resolution
(40.2% for the last resolution shell). Electron density was improved by averag-
ing and back-transforming reflections 10 times over the two-fold noncrystallo-
graphic symmetry axis using the program package MAIN (Turk, 1992). Con-
ventional crystallographic rigid body, positional, and temperature factor
refinements were performed with CNS using the yeast 20S proteasome struc-
ture as the starting model (Groll et al., 1997). For model building, the program
MAIN was used. The structure was refined to a crystallographic R factor of
24.0% (free R factor 26.5%; Bru¨nger, 1993) with root-mean-square deviations
from target values of 0.007 A˚ for bonds and 1.37 for angles (Bru¨nger, 1993).
Modeling experiments were performed using the coordinates of yeast 20S
proteasome (Groll et al., 1997) with the program MAIN.
Luciferase Reporter Promoter Activity Assay
Using primer-directed PCR, truncated versions of the previously cloned NGF
promoter were created and inserted into the promoterless luciferase expres-
sion vector pGL4 (Promega Corp.). Reporter constructs were then stably
transfected into NIH 3T3 cells using LipofecatAMINE 2000; pools of stably
transfected clones were used for the analysis of each reporter construct. The
stably transfected cells were tested for their ability to up-regulate luciferase ac-
tivity in response to proteasome inhibitors using the Dual Luciferase Reporter
Assay System (Promega Corp.). An SV40 early promoter-driven renilla lucifer-
ase construct (Promega Corp.) was used as a coreporter to normalize results.
ACCESSION NUMBERS
Atomic coordinates have been deposited in the RCSB Protein Data Bank
(http://www.rcsb.org/pdb) under the accession code 3D29 (yeast 20S protea-
some-fellutamide B complex).
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